(Q45074002)

English

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

scientific article published in March 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 December 2017

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study (English)

1 reference

Europe PubMed Central

9 December 2017

type 2 diabetes

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Matthews DR

1

1 reference

Europe PubMed Central

9 December 2017

Charbonnel BH

2

1 reference

Europe PubMed Central

9 December 2017

Hanefeld M

3

1 reference

Europe PubMed Central

9 December 2017

Brunetti P

4

1 reference

Europe PubMed Central

9 December 2017

Schernthaner G

5

1 reference

Europe PubMed Central

9 December 2017

publication date

1 March 2005

1 reference

Europe PubMed Central

9 December 2017

Diabetes - Metabolism: Research and Reviews

1 reference

Europe PubMed Central

9 December 2017

21

1 reference

Europe PubMed Central

9 December 2017

2

1 reference

Europe PubMed Central

9 December 2017

167-174

1 reference

Europe PubMed Central

9 December 2017

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

21 January 2018

Hyperinsulinemic microalbuminuria. A new risk indicator for coronary heart disease.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

21 January 2018

Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral combination therapy for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

Laboratory surrogates for anti-atherosclerotic drug development

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimizing the diabetic formulary: beyond aspirin and insulin

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

LDL particle size in relation to insulin, proinsulin, and insulin sensitivity. The Insulin Resistance Atherosclerosis Study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of increased liver triglyceride content: a culprit of diabetic hyperglycaemia?

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.478

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DMRR.478

1 reference

Europe PubMed Central

9 December 2017

1 reference

Europe PubMed Central

9 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45074002&oldid=2064573471"